NeuroInvestment today announced the release of its June issue, which reviews novel analgesics being developed for the treatment of alertness and excessive daytime sleepiness (EDS). This category covers a broad
range of pathology, ranging from the truly devastating effects of narcolepsy,
to the widespread but modest effects of circadian rhythm disruption, due to shiftwork
changes or jet lag.